Nadia Mizrahi

NEW

Profile

Patent and Intellectual Property Counsel for Israeli Innovation

Nadia Mizrahi advises Chinese technology companies on patent prosecution in Israel, technology transfer agreements, and cross-border innovation partnerships from Heskia - Hacmun Law Firm in Tel Aviv.

Israel has become a significant source of deep technology for Chinese investors, particularly in agritech, water technology, medical devices, and cybersecurity. Her practice bridges the IP systems of both countries, helping Chinese firms secure and enforce patent rights in Israel while structuring technology acquisition and licensing arrangements with Israeli innovation companies.

Patent Prosecution and Portfolio Management

The Israel Patent Office operates under the Patents Law 5727-1967, which has been modernized through successive amendments to align with international standards. She manages the full patent lifecycle from prior art searching and specification drafting through examination, office action response, opposition proceedings, and grant. Her prosecution strategy accounts for Israel's unique grace period provisions and utility model system, which differ materially from Chinese patent practice.

Chinese companies acquiring Israeli technology assets frequently overlook the distinctions between Israeli and Chinese patent enforcement frameworks. The Israel Patent Office does not conduct substantive examination on utility models. Patent term extensions are available for pharmaceutical and certain medical device patents where regulatory approval causes commercialization delays.

Technology Transfer and Licensing

Israeli technology transfer is governed by a combination of contractual freedom under Israeli contract law and regulatory oversight for certain sectors such as defense and cybersecurity. She structures cross-border licensing agreements that address patent royalty calculations, territorial scope, sublicensing rights, grant-back provisions on improvements, and dispute resolution mechanisms. Technology transfer agreements involving Israeli academic institutions require navigation of the Technology Transfer Company (TTC) framework, which governs how university-derived IP is commercialized.

Client Considerations

Chinese investors acquiring Israeli patented technology should conduct Israeli-specific IP due diligence covering ownership chain, inventorship determinations (Israeli law applies the "first to file" but with different inventorship standards than China), government approval requirements for certain technology exports, and existing third-party licensing commitments that may restrict assignment or exclusivity.

Professional Standards

Education: Tel Aviv University, LL.B.; Hebrew University, LL.M.
Languages: Hebrew, English, Mandarin Chinese
Bar Admission: 2011
Firm: Heskia - Hacmun Law Firm

Patent Enforcement and Litigation Support

Israeli patent litigation is conducted before the Tel Aviv District Court and the Israel Patent Office in opposition and cancellation proceedings. She coordinates with local litigation counsel on infringement analysis, claim construction, discovery procedures under Israeli civil procedure, preliminary injunction applications, and damages assessment. Israeli courts award both actual damages and reasonable royalties.

IP Strategy for Chinese-Israeli Joint Ventures

Chinese companies entering into joint ventures with Israeli technology companies require careful IP allocation provisions in their collaboration agreements. She structures agreements that address background IP ownership, foreground IP allocation, joint ownership arrangements including enforcement and licensing rights, confidentiality obligations, and territorial restrictions on technology exploitation.

Patent Prosecution Highway and Accelerated Examination

The Israel Patent Office participates in the Patent Prosecution Highway (PPH) with the US Patent and Trademark Office, the Japan Patent Office, and the Korean Intellectual Property Office. Under PPH, applicants whose claims have been found allowable by a participating office may request accelerated examination of corresponding applications at the Israel Patent Office. This significantly reduces prosecution time and examination costs. She also advises on the grant of Patent Term Extension for pharmaceutical and medical device patents where regulatory approval by the Ministry of Health causes commercialization delays. China-Israel patent cooperation has increased significantly under the Belt and Road Initiative IP cooperation framework.

Trade Secret Protection in Israel

Israeli law protects trade secrets and confidential business information under the Commercial Torts Law 5759-1999 and the Securities Law. Protection requires that the information be secret, have commercial value, and be subject to reasonable steps to maintain confidentiality. She advises Chinese technology investors on Israeli trade secret protection including confidentiality agreement drafting, employee invention assignment provisions, access control policies, technology transfer documentation, and enforcement options including preliminary injunctions and damages claims.

Industrial design registration in Israel is available through the Israel Patent Office for product designs that are novel and have individual character. Unregistered design protection is also available under Israeli law for a period of three years from first disclosure. Plant variety protection is administered separately through the Ministry of Agriculture. Utility model protection is not available in Israel, meaning that incremental innovations that might qualify as utility models in China or Germany require full patent protection in Israel. She advises Chinese agricultural and biotechnology companies on plant breeder rights registration, enforcement against unauthorized propagation, and royalty collection from Israeli seed producers and distributors.

Her cross-border practice also addresses the intersection of IP protection with Israeli export control regulations administered by the Ministry of Defense, which can restrict the transfer of certain dual-use technologies. Chinese investors in Israeli defense or cybersecurity technologies should conduct thorough regulatory due diligence before completing technology transfer arrangements.

Her practice also extends to advising Chinese life sciences companies on patent strategy for the Israeli pharmaceutical market, including supplemental protection certificate eligibility and pediatric extension programs under Israeli patent law.